

Best Available Copy  
PATENT COOPERATION TREATY

PCT

COMMUNICATION OF  
INTERNATIONAL APPLICATIONS

(PCT Article 20)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as designated Office

Date of mailing:

15 November 2000 (15.11.00)

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:

PCT/GB00/01787

International publication no.:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra  
Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

RECOMMANDÉ

ANNEXE

PCT

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
ERIC POTTER CLARKSON  
Attn. BASSETT, Richard S.  
Park View House  
58 The Ropewalk  
Nottingham NG1 5DD  
UNITED KINGDOM

## INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

ACTIONED BY:

Date of mailing  
(day/month/year)

26/02/2001

Applicant's or agent's file reference

WARM/P22402PC

PAYMENT DUE

within 30 ~~XXXX~~ days  
from the above date of mailing

International application No.

PCT/GB 00/ 01787

International filing date  
(day/month/year)

10/05/2000

Applicant

WARNER-LAMBERT COMPANY et al.

## 1. This International Searching Authority

- (i) considers that there are 10 (number of) inventions claimed in the international application covered by the claims indicated ~~below~~ on the extra sheet:

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated ~~below~~ on the extra sheet:

- (ii) ☒ has carried out a partial international search (see Annex) ☐ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.:

SEE ANNEX

- (iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid

## 2. The applicant is hereby invited, within the time limit indicated above, to pay the amount indicated below:

GBP 572.00 x 9 = GBP 5.148.00  
Fee per additional invention      number of additional inventions      total amount of additional fees

Or, EUR 945.00 x 9 = EUR 8.505.00

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☒ Claim(s) Nos. SEE ANNEX have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Joannes Vergoosen

5771-01-MG

09/700,165

## INVITATION TO PAY ADDITIONAL FEES

International application No.

PCT/GB 00/01787

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-2, 17, 18, 19, 30 (partial); 3, 4, 20, 21, (complete).

Pharmaceutical compositions for the treatment and prevention of sexual dysfunctions comprising compounds as disclosed in the Markush formula in claim 1.

2. Claims: 1-2, 17, 18, 19, 30 (partial ), 5, 22, (complete).

Pharmaceutical compositions for the treatment of anxiety, panic disorders and social phobia comprising compounds as disclosed in the Markush formula in claim 1.

3. Claims: 1-2, 17, 18, 19, 30 (partial ), 6, 23 (complete).

Pharmaceutical compositions for the treatment of pulmonary hypertension comprising compounds as disclosed in the Markush formula in claim 1.

4. Claims: 1-2, 17, 18, 19, 30 (partial ), 7, 24 (complete).

Pharmaceutical compositions for the treatment lung development disorders and lung repair comprising compounds as disclosed in the Markush formula in claim 1.

5. Claims: 1-2, 17, 18, 19, 30 (partial ), 8, 9, 34-40 (complete).

Pharmaceutical compositions for the treatment of prostate cancer and pancreatic cancer comprising compounds as disclosed in the Markush formula in claim 1.

6. Claims: 1-2, 17, 18, 19, 30 (partial ), 10, 25 (complete).

Pharmaceutical compositions for the treatment of hepatic porphyria comprising compounds as disclosed in the Markush formula in claim 1.

7. Claims: 1-2, 17, 18, 19, 30 (partial ), 11, 16, 26, 29 (complete).

Pharmaceutical compositions for the treatment of visceral pain, inflammatory pain, neuropathic pain, cancer pain, postoperative pain, trigeminal neuralgia pain, acute herpetic pain, post herpetic pain, comprising compounds as disclosed in the Markush formula in claim 1.

## INVITATION TO PAY ADDITIONAL FEES

International application No.

PCT/GB 00/01787

8. Claims: 1-2,17,18,19,30 (partial ), 12,13, 27 (complete).

Pharmaceutical compositions for the treatment of gastrointestinal secretory disturbances comprising compounds as disclosed in the Markush formula in claim 1.

9. Claims: 1-2,17,18,19,30 (partial ), 14, 15, 28 (complete).

Pharmaceutical compositions for the treatment of emesis or anorexia comprising compounds as disclosed in the Markush formula in claim 1.

10. Claims: 10th 31-33, 41-42 (complete).

Compositions for the diagnosis of cancer comprising compounds as disclosed in the Markush formula in claim 31.

The problem to be solved by the present application is to provide pharmaceutical compositions for the treatment of diseases amenable to therapy by a bombesin receptor antagonist. These diseases are listed in the description at page 2 lines 3-9. Furthermore the inventors intend to provide compositions for the diagnosis of cancer. As solution to the above mentioned problems the inventors provide pharmaceutical compositions comprising antagonists of the bombesin receptor having the structure as shown in the Markush formula in claim 1.

Rule 13.1 PCT deals with the requirement of unity of invention, and states the principle that an international application should relate to only one invention or, if there is more than one invention, that the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept. Rule 13.2 PCT defines the method for determining whether the requirement of unity of invention is satisfied in respect of a group of inventions claimed in an international application. Unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding "special technical features." The expression "special technical features" is defined in Rule 13.2, as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art.

The problem underlying the present application has found similar solutions in the prior art.

WO9807718 discloses bombesin receptor antagonists having the same structure of the compounds of the present application, for the treatment of depression, psychosis, affective disorders, cancer, gastrointestinal diseases and other diseases.

Bioorg. Med. Chem. Lett. VOL. 8 N. 18, Pg. 2589-2594; J. Med. Chem. 1993, 36, 2868-2877; and Eur. Journ. Chem. 1994, 29, 431-439 also disclose some of the bombesin receptor antagonists disclosed in the present application and their pharmacological properties in regard to

## INVITATION TO PAY ADDITIONAL FEES

International application No.

PCT/GB 00/01787

some of the above mentioned diseases.

The idea use to bombesin receptor antagonists for the treatment of the above mentioned diseases, is consequently known in the state of the art, and cannot serve as a single general inventive concept.

In the present application no further technical feature(s) can be distinguished that can be regarded as a "special technical feature" involved in the technical relationship among the different inventions. Consequently, the present application lacks unity of invention, and the different solutions not belonging to a common inventive concept are identified as the different subjects listed above. Each of the inventions listed is a distinct invention, characterised by its own special technical feature, defining the contribution which each of the claimed inventions, considered as a whole, makes over the prior art, i.e. the use of the cited compound in relation to the treatment of each group of above mentioned diseases.

Searching these different subjects would have caused a major additional searching effort.

Only the first subject was searched.

International Application No. PCT/GB 00 0178;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Continuation of Box 3.

Although claims 1-4, 17-21, 30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Annex to Form PCT/ISA/206  
**COMMUNICATION RELATING TO THE RESULTS  
 OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No

PCT/GB 00/01787

1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- see 'Invitation to pay additional fees'
2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
3. If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
4. If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
E	✓ WO 00 37462 A (HORWELL DAVID CHRISTOPHER ; LEWTHWAITE RUSSELL ANDREW (GB); RAPHY J) 29 June 2000 (2000-06-29) claims 1,14; examples	1-4, 18-21
A	WO 98 07718 A (HORWELL DAVID CHRISTOPHER ; PRITCHARD MARTYN CLIVE (GB); WARNER LAM) 26 February 1998 (1998-02-26) cited in the application the whole document	1,2, 17-19,30
A	ASHWOOD V ET AL: "PD 176252 - The First High Affinity Non-peptide Gastrin-Releasing Peptide (BB2) Receptor Antagonist" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 8, no. 18, 22 September 1998 (1998-09-22); pages 2589-2594, XP004138276 ISSN: 0960-894X table 3	17,30
A	✓ US 5 200 408 A (BRU-MAGNIEZ NICOLE ET AL) 6 April 1993 (1993-04-06) page W	1,2, 18-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* "Z" document member of the same patent family

Annex to Form PCT/ISA/206

COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH

International Application No

PCT/GB 00/01787

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	✓ BLOMMAERT A G S ET AL: "CHOLECYSTOKININ PEPTIDOMIMETICS AS SELECTIVE CCK-B ANTAGONISTS: DESIGN, SYNTHESIS, AND IN VITRO AND IN VIVO BIOCHEMICAL PROPERTIES" JOURNAL OF MEDICINAL CHEMISTRY, 1993, XP002050616 figure 1; table 1	1,2,18, 20
A	✓ SARTORI E ET AL: "SYNTHESIS AND ANALGESIC ACTIVITIES OF UREA DERIVATIVES OF ALPHA-AMINO-N-PYRIDYL BENZENE PROPANAMIDE" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 29, no. 6, 1994, pages 431-439, XP000917148 ISSN: 0223-5234 tables 1-5	1,2,18, 20

## Patent Family Annex

International Application No

Information on patent family members

PCT/GB 00/01787

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0037462	A	29-06-2000	AU 2180600 A	12-07-2000
WO 9807718	A	26-02-1998	AU 4146697 A	06-03-1998
			BR 9711342 A	17-08-1999
			EP 0920424 A	09-06-1999
			NO 990788 A	19-02-1999
			PL 331710 A	02-08-1999
			TR 9900364 T	21-05-1999
US 5200408	A	06-04-1993	FR 2687147 A	13-08-1993

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>WL-5771-PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 00/ 04915</b>	International filing date (day/month/year) <b>20/12/2000</b>	(Earliest) Priority Date (day/month/year)
Applicant <b>WARNER - LAMBERT COMPANY</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 7 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**

- ☐ the text is approved as submitted by the applicant.
- ☒ the text has been established by this Authority to read as follows:

**NOVEL USES OF NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS FOR TREATING ANXIETY AND PANIC DISORDERS**

**5. With regard to the abstract,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 00/04915

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-3, 8-15, 20-24
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3,20-23 (partially)

Use of compounds derived of urea for treating anxiety and panic disorders, social phobia.

2. Claims: 1-3,20-23 (partially)

Use of compounds derived of urea for treating pulmonary hypertension, lung repair and lung development disorder.

3. Claims: 1-3,20-23 (partially),8-14,15(partially),24

Use of compounds derived of urea for treating prostate cancer, pancreatic cancer.

4. Claims: 1-3,20-23 (partially)

Use of compounds derived of urea for treating pain of different origins.

5. Claims: 1-3,20-23 (partially), 4

Use of compounds derived of urea for treating gastrointestinal secretory disturbance.

6. Claims: 1-3,20-23 (partially)

Use of compounds derived of urea for treating hepatic porphyria.

7. Claims: 5-7,15 (partially),25

Use of compounds derived of urea for diagnostic imaging of a tumour.

8. Claims: 16-19

Method for in vitro detection of a cancer cell, which includes in vitro contacting of the cells with the compound claimed.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 20-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.  
Although claim 23 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

Present claims 1,8-15,20-24 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search for the first invention has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds described in claims 2,3.

Claims searched completely: 2-3.

Claims searched incompletely: 1,8-15,20-24.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04915

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4164 A61K31/44 A61K31/404 A61P25/22 A61P25/24

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, WPI Data, PAJ, EMBASE, MEDLINE, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 07718 A (HORWELL DAVID CHRISTOPHER ;PRITCHARD MARTYN CLIVE (GB); WARNER LAM) 26 February 1998 (1998-02-26) page 2, line 8 - line 12 claims 10-13 page 4, line 1 page 7, line 14 - line 23 page 4</p> <p style="text-align: center;">--- -/-</p>	1,2, 20-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

19 December 2001

Date of mailing of the international search report

18.01.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Bonzano, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04915

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ASHWOOD, V. ET AL: "PD 176252 - the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist" BIOORG. MED. CHEM. LETT. (1998), 8(18), 2589-2594, XP004138276 page 2589, paragraph 3 -page 2590, paragraph 1 table 3 page 2593, paragraph 3 example 6; table 1 ---	1-3, 20-23
X	RYAN RICHARD R ET AL: "Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 290, no. 3, 1999, pages 1202-1211, XP000917708 ISSN: 0022-3565 page 1202, column 2, line 13 -page 1203, column 1, line 13 page 1210, column 1, paragraph 2 ---	1,2, 20-24
X	TOKITA, KENJI ET AL: "Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368" J. BIOL. CHEM. (2001), 276(1), 495-504, XP001020363 page 495, column 2, paragraph 2 ---	1,2, 8-15, 20-24
A	VARIOUS: "The Merck manual" , BEERS AND BERKOW , N.J. XP002186135  page 988, column 1, paragraph 3 - paragraph 5 ---	1-3, 8-15, 20-24
X	MOODY, T. W. ET AL: "Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells" EUR. J. PHARMACOL. (2000), 409(2), 133-142, XP001020329 page 133, column 1, line 1 -column 2, line 15 page 134, column 2, paragraph 3 ---	1-3, 8-15, 20-24
	--- -/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04915

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOODY T.W. ET AL: "Bombesin receptor antagonists." DRUGS OF THE FUTURE, (1998) 23/12 (1305-1315). , XP001020387 page 1305, column 1, paragraph 1 page 1311, column 1, line 17 - line 29 -----	1,2, 8-15, 20-24

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/GB 00/04915

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9807718	A	26-02-1998	AU 733226 B2 10-05-2001
			AU 4146697 A 06-03-1998
			BR 9711342 A 17-08-1999
			EP 0920424 A1 09-06-1999
			JP 2001500850 T 23-01-2001
			NO 990788 A 19-02-1999
			PL 331710 A1 02-08-1999
			TR 9900364 T2 21-05-1999
			WO 9807718 A1 26-02-1998
			US 6194437 B1 27-02-2001

---

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving office use only

International Application No. **PCT/GB 00 / 01787**

International Filing Date. **10 MAY 2000**  
**10 05 00**

Name of receiving office and PCT International Application  
**United Kingdom Patent Office  
PCT International Application**

Applicant's or agent's file reference  
(if desired) (12 characters maximum) **WARM / P22402PC**

Box No. I **TITLE OF INVENTION**

**NOVEL USES OF NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS**

Box No. II **APPLICANT**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

Warner-Lambert Company  
201 Tabor Road  
Morris Plains  
New Jersey  
07950  
USA

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality: **US**

State (that is, country) of residence: **US**

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III **FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

PINNOCK, Robert Denham  
3 Teasel Way  
Cambridge  
CB1 9YT  
United Kingdom

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (if this check-box is marked, do not fill in below.)

State (that is, country) of nationality: **GB**

State (that is, country) of residence: **GB**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV **AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Bassett, Richard S  
Eric Potter Clarkson  
Park View House  
58 The Ropewalk  
Nottingham. NG1 5DD  
GB

Telephone No. (0115) 9552211

Facsimile No. (0115) 9552201

Teleprinter No. 37540 Potter G

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) PRITCHARD, Martyn Clive The Maples, 9 Bury Close St Ives Huntingdon Cambridgeshire PE17 4WB United Kingdom	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (if this check-box is marked, do not fill in below.)
---	---

State (that is, country) of nationality: GB

State (that is, country) of residence: GB

 This person is applicant for the purposes of: ☐ all designated states ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) GONZALEZ, Maria Isabel 55 Saint Barnabas Road Cambridge CB1 2BX United Kingdom	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (if this check-box is marked, do not fill in below.)
---	---

State (that is, country) of nationality: ES

State (that is, country) of residence: GB

 This person is applicant for the purposes of: ☐ all designated states ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	This person is:  <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (if this check-box is marked, do not fill in below.)
---	--

State (that is, country) of nationality:

State (that is, country) of residence:

 This person is applicant for the purposes of: ☐ all designated states ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)	This person is:  <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (if this check-box is marked, do not fill in below.)
---	--

State (that is, country) of nationality:

State (that is, country) of residence:

 This person is applicant for the purposes of: ☐ all designated states ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

## Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

## Regional Patent

- ☒ **AP** **ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** **Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** **European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** **OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....

## National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> <b>AE</b> United Arab Emirates                  | <input checked="" type="checkbox"/> <b>LR</b> Liberia                                   |
| <input checked="" type="checkbox"/> <b>AL</b> Albania                               | <input type="checkbox"/> <b>LS</b> Lesotho  |
| <input type="checkbox"/> <b>AM</b> Armenia  | <input checked="" type="checkbox"/> <b>LT</b> Lithuania                                 |
| <input type="checkbox"/> <b>AT</b> Austria  | <input type="checkbox"/> <b>LU</b> Luxembourg   |
| <input type="checkbox"/> <b>AU</b> Australia  | <input type="checkbox"/> <b>LV</b> Latvia   |
| <input type="checkbox"/> <b>AZ</b> Azerbaijan                                       | <input checked="" type="checkbox"/> <b>MA</b> Morocco                                   |
| <input checked="" type="checkbox"/> <b>BA</b> Bosnia and Herzegovina                | <input type="checkbox"/> <b>MD</b> Republic of Moldova                                  |
| <input checked="" type="checkbox"/> <b>BB</b> Barbados                              | <input checked="" type="checkbox"/> <b>MG</b> Madagascar                                |
| <input checked="" type="checkbox"/> <b>BG</b> Bulgaria                              | <input checked="" type="checkbox"/> <b>MK</b> The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> <b>BR</b> Brazil                                | <input type="checkbox"/> <b>MN</b> Mongolia   |
| <input type="checkbox"/> <b>BY</b> Belarus  | <input type="checkbox"/> <b>MW</b> Malawi   |
| <input checked="" type="checkbox"/> <b>CA</b> Canada                                | <input type="checkbox"/> <b>MX</b> Mexico   |
| <input checked="" type="checkbox"/> <b>CH and LI</b> Switzerland and Liechtenstein  | <input type="checkbox"/> <b>NO</b> Norway   |
| <input checked="" type="checkbox"/> <b>CN</b> China                                 | <input checked="" type="checkbox"/> <b>NZ</b> New Zealand                               |
| <input checked="" type="checkbox"/> <b>CR</b> Costa Rica                            | <input checked="" type="checkbox"/> <b>PL</b> Poland                                    |
| <input checked="" type="checkbox"/> <b>CU</b> Cuba                                  | <input type="checkbox"/> <b>PT</b> Portugal   |
| <input checked="" type="checkbox"/> <b>CZ</b> Czech Republic                        | <input checked="" type="checkbox"/> <b>RO</b> Romania                                   |
| <input type="checkbox"/> <b>DE</b> Germany  | <input type="checkbox"/> <b>RU</b> Russian Federation                                   |
| <input type="checkbox"/> <b>DK</b> Denmark  | <input type="checkbox"/> <b>SD</b> Sudan  |
| <input checked="" type="checkbox"/> <b>DM</b> Dominica                              | <input type="checkbox"/> <b>SE</b> Sweden   |
| <input type="checkbox"/> <b>EE</b> Estonia  | <input checked="" type="checkbox"/> <b>SG</b> Singapore                                 |
| <input type="checkbox"/> <b>ES</b> Spain  | <input checked="" type="checkbox"/> <b>SI</b> Slovenia                                  |
| <input type="checkbox"/> <b>FI</b> Finland  | <input checked="" type="checkbox"/> <b>SK</b> Slovakia                                  |
| <input type="checkbox"/> <b>GB</b> United Kingdom                                   | <input checked="" type="checkbox"/> <b>SL</b> Sierra Leone                              |
| <input checked="" type="checkbox"/> <b>GD</b> Grenada                               | <input type="checkbox"/> <b>TJ</b> Tajikistan   |
| <input checked="" type="checkbox"/> <b>GE</b> Georgia                               | <input type="checkbox"/> <b>TM</b> Turkmenistan   |
| <input type="checkbox"/> <b>GH</b> Ghana  | <input checked="" type="checkbox"/> <b>TR</b> Turkey                                    |
| <input type="checkbox"/> <b>GM</b> Gambia   | <input checked="" type="checkbox"/> <b>TT</b> Trinidad and Tobago                       |
| <input checked="" type="checkbox"/> <b>HR</b> Croatia                               | <input type="checkbox"/> <b>TZ</b> United Republic of Tanzania                          |
| <input checked="" type="checkbox"/> <b>HU</b> Hungary                               | <input checked="" type="checkbox"/> <b>UA</b> Ukraine                                   |
| <input checked="" type="checkbox"/> <b>ID</b> Indonesia                             | <input type="checkbox"/> <b>UG</b> Uganda   |
| <input checked="" type="checkbox"/> <b>IL</b> Israel                                | <input checked="" type="checkbox"/> <b>US</b> United States of America                  |
| <input checked="" type="checkbox"/> <b>IN</b> India                                 | <input type="checkbox"/> <b>UZ</b> Uzbekistan   |
| <input type="checkbox"/> <b>IS</b> Iceland  | <input checked="" type="checkbox"/> <b>VN</b> Viet Nam                                  |
| <input type="checkbox"/> <b>JP</b> Japan  | <input checked="" type="checkbox"/> <b>YU</b> Yugoslavia                                |
| <input type="checkbox"/> <b>KE</b> Kenya  | <input checked="" type="checkbox"/> <b>ZA</b> South Africa                              |
| <input type="checkbox"/> <b>KG</b> Kyrgyzstan                                       | <input type="checkbox"/> <b>ZW</b> Zimbabwe   |
| <input checked="" type="checkbox"/> <b>KP</b> Democratic People's Republic of Korea |   |
| <input type="checkbox"/> <b>KR</b> Republic of Korea                                |   |
| <input type="checkbox"/> <b>KZ</b> Kazakhstan                                       |   |
| <input checked="" type="checkbox"/> <b>LC</b> Saint Lucia                           |   |
| <input checked="" type="checkbox"/> <b>LK</b> Sri Lanka                             |   |

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:

- ☒ **DZ** Algeria
- ☒ **AG** Antigua and Barbuda

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

**Box No. VI PRIORITY CLAIM**☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		National application: Country	regional application:* regional Office	international application: receiving Office
item (1) 10 May 1999 (10/05/1999)	60/133,355	US	/	
item (2)				
item (3)				

☐ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s):

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

**Choice of International Searching Authority (ISA)**  
(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA /

**Request to use results of earlier search; reference to that search** (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

**Box No. VIII CHECK LIST; LANGUAGE OF FILING**

This international application contains the following number of sheets:

request : 4 ✓  
description (excluding  
sequence listing part) : 28 ✓  
claims : 13 ✓  
abstract : 1 ✓  
drawings : 6 ✓  
sequence listing part of  
description : 0 ✓  
**Total number of sheets** : 52 ✓

This international application is accompanied by the item(s) marked below:

- ☒ fee calculation sheet
- ☒ separate signed power of attorney
- ☒ copy of general power of attorney; reference number, if any:
- ☐ statement explaining lack of signature
- ☒ priority document(s) identified in Box No. VI as item(s): (1)
- ☐ translation of international application into (language):
- ☐ separate indications concerning deposited microorganism or other biological material
- ☐ nucleotide and/or amino acid sequence listing in computer readable form
- ☐ other (specify):

**Figure of the drawings** which should accompany the abstract: 1

**Language of filing of the International application:** English

**Box No. IX SIGNATURE OF APPLICANT OR AGENT**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

  
**I.E. Stevens**

Richard S Bassett

For receiving Office use only

1. Date of actual receipt of the purported international application: 10 MAY 2000 10 05 00	2. Drawings: <input checked="" type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA /	6. <input checked="" type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

Date of receipt of the record copy by the International Bureau:

08 JUNE 2000

For International Bureau use only

(08.06.00)

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>WLB0C001-PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 00/ 04380</b>	International filing date (day/month/year) <b>17/11/2000</b>	(Earliest) Priority Date (day/month/year)
Applicant <b>WARNER-LAMBERT COMPANY INC. et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 00/04380

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-9, 11-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1-24 relate to compounds defined by reference to a desirable characteristic or property, namely the activity as (peptide or non-peptide) bombesin receptor antagonist, with eventually affinity for the BB1 receptor, vasodilator, (modulator of) steroid hormones, neurotransmitter agonist or antagonist, hormone product usefu for the treatment of sexual dysfunctions, a monoamine synthesis modifier, a monoamine metabolism or uptake modifier useful for the treatment of sexual dysfunctions, a PDE5 inhibitor, a VIP enhancer, a compound that promotes production of NO, oestrogens, androgens.

The claims cover all compounds and combinations having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds for which pharmacological data have been presented in the description, and the compounds/products which are fully defined in the claims.

Claims searched completely: none.

Claims searched incompletely: 1-24.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04380

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K31/454 A61P15/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 37462 A (HORWELL DAVID CHRISTOPHER ;LEWTHWAITE RUSSELL ANDREW (GB); RAPHY J) 29 June 2000 (2000-06-29)	1-8, 10
Y	claims 7, 14 page 63, line 1 - line 8 page 85; example 226 page 71; example 89 ---	11-24
Y	US 5 650 395 A (HUREL STEVEN) 22 July 1997 (1997-07-22)  column 2, paragraph 3 ---	11, 13-18, 20-24
Y	EP 1 057 829 A (JORDANIAN PHARMACEUTICAL CO. LTD.) 6 December 2000 (2000-12-06)  page 2, line 5 - line 20 page 4, line 7 - line 14 ---	11, 13-18, 20-24
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

12 July 2001

Date of mailing of the international search report

19/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Bonzano, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04380

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 67708 A (ALI VASSEM ;UNIV TEXAS (US)) 16 November 2000 (2000-11-16) page 4, line 18 - line 27 page 5, line 30 - line 33 ---	12,19
A	WO 98 07718 A (HORWELL DAVID CHRISTOPHER ;PRITCHARD MARTYN CLIVE (GB); WARNER LAM) 26 February 1998 (1998-02-26) example 1 page 2, line 8 - line 12 ---	1-24
A	ASHWOOD V ET AL: "PD 176252 - The First High Affinity Non-peptide Gastrin-Releasing Peptide (BB2) Receptor Antagonist" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 8, no. 18, 22 September 1998 (1998-09-22), pages 2589-2594, XP004138276 ISSN: 0960-894X page 2589, paragraph 1 - paragraph 2 table 1 ---	1-10
A	US 5 369 094 A (SCHALLY ANDREW VICTOR ET AL) 29 November 1994 (1994-11-29) column 15, line 26 - line 35 column 1, line 37 - line 49 -----	9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04380

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0037462	A	29-06-2000	AU	2180600 A	12-07-2000
US 5650395	A	22-07-1997	AU	5145196 A	02-10-1996
			WO	9628214 A	19-09-1996
EP 1057829	A	06-12-2000	NONE		
WO 0067708	A	16-11-2000	AU	4825200 A	21-11-2000
WO 9807718	A	26-02-1998	AU	733226 B	10-05-2001
			AU	4146697 A	06-03-1998
			BR	9711342 A	17-08-1999
			EP	0920424 A	09-06-1999
			JP	2001500850 T	23-01-2001
			NO	990788 A	19-02-1999
			PL	331710 A	02-08-1999
			TR	9900364 T	21-05-1999
			US	6194437 B	27-02-2001
US 5369094	A	29-11-1994	US	5244883 A	14-09-1993
			AT	167874 T	15-07-1998
			AU	666270 B	01-02-1996
			AU	6444694 A	11-10-1994
			BR	9404341 A	31-08-1999
			CA	2135787 A	29-09-1994
			CZ	9402807 A	12-07-1995
			DE	69411342 D	06-08-1998
			DE	69411342 T	19-11-1998
			DK	646127 T	12-04-1999
			EP	0646127 A	05-04-1995
			ES	2120615 T	01-11-1998
			FI	945378 A	15-11-1994
			HR	940164 A	31-08-1996
			HU	69727 A, B	28-09-1995
			JP	7507330 T	10-08-1995
			NO	944293 A	02-01-1995
			NZ	263668 A	24-06-1997
			PL	306209 A	06-03-1995
			RU	2114118 C	27-06-1998
			SI	9420001 A, B	31-08-1995
			SK	136494 A	09-08-1995
			WO	9421674 A	29-09-1994
			ZA	9401767 A	06-10-1994
			AT	120760 T	15-04-1995
			AU	657723 B	23-03-1995
			AU	9064591 A	25-06-1992
			CA	2097192 A	30-05-1992
			CZ	9301006 A	16-03-1994
			DE	69108738 D	11-05-1995
			DE	69108738 T	17-08-1995
			DK	559756 T	19-06-1995
			EP	0559756 A	15-09-1993
			ES	2072137 T	01-07-1995
			FI	932457 A	28-05-1993
			GR	3015866 T	31-07-1995
			HR	921277 A	31-08-1997
			HU	213114 B	28-02-1997
			HU	64566 A	28-01-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04380

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5369094 A		HU 9500466 A	28-09-1995
		IE 914140 A, B	03-06-1992
		JP 6503090 T	07-04-1994
		KR 225679 B	15-10-1999
		LV 5794 A	20-02-1997
		MC 2326 A	18-01-1994
		NO 931977 A	28-05-1993
		NZ 240628 A	26-07-1994
		PL 169498 B	31-07-1996
<hr/>			